Delivering therapeutic agents for successful outcomes

Current research being conducted by faculty and students involves improving the efficacy and delivery of a broad range of therapeutic agents, from small molecules to biologics such as proteins, antibodies, oligonucleotides, genes, and cells.

Drug-delivery systems are tested in cell-based functional assays, animal disease models, or humans using pharmacokinetic and pharmacodynamic assessments and clinical outcomes. Due to the interdisciplinary nature of research, most projects are in collaboration with colleagues of relevant expertise.

Pharmacoengineering and Molecular Pharmaceutics represent interdisciplinary specialties within the pharmaceutical sciences and encompass a range of scientific endeavors, including:

  • The design, engineering, fabrication, and evaluation of dosage forms and delivery strategies for conventional and biotechnology-based therapeutic agents.
  • Elucidation of barriers to systemic and target-specific drug delivery.
  • Determination of the ability of pharmacologic agents to reach the relevant site of biologic effect and their time course of biologic activity.

These areas represent critical steps in the development of new therapeutic agents, the evaluation of new and existing agents in a variety of settings (e.g., potential interactions with other agents or alterations secondary to physiologic changes associated with disease processes), and the optimal clinical use of pharmacologic agents.


Research Facilities

Marsico Hall

Marisco Hall is one of the largest buildings on the UNC Chapel Hill campus and houses basic and translational research across several disciplines. The building includes the Marsico Lung Institute, the Biomedical Research Imaging Center, and researchers from UNC Lineberger Comprehensive Cancer Center, nanomedicine, microbiology and immunology, and pharmacoengineering.

Pharmacy researchers with labs in Marsico Hall include members of the UNC Eshelman School of Pharmacy’s Division of Chemical Biology and Medicinal Chemistry, Division of Pharmacoengineering and Molecular Pharmaceutics, Center for Integrative Chemical Biology and Drug Discovery and the Center for Nanotechnology in Drug Delivery.

kristy_ainslie

Kristy Ainslie Lab

Kristy Ainslie’s lab aims to design practical and innovative formulations, taking into account the scalable production and applications in developing nations.

aaron_anselmo

Aaron Anselmo Lab

The Anselmo lab focuses on understanding microbe-material-host tissue interactions to develop: (i) formulations for the improved delivery of therapeutic microbes, (ii) materials-based in vitro culture approaches to enable the co-culture of microbial ecologies alongside mammalian cells, and (iii) targeted approaches for the delivery of therapeutic microbes.

shawn_hingtgen

Shawn Hingtgen – Targeted Cellular Therapeutic and Imaging Lab

In the Hingtgen lab, we seek to harness the potential of stem cells to develop new and better methods for treating terminal cancers, including brain cancer. We use an integrative approach that begins with creating specially designed targeted therapeutic proteins.

leaf_huang

Leaf Huang – Laboratory of Drug Targeting

The Laboratory of Drug Targeting has been working on liposomes and immunoliposomes for drug delivery.

michael_jay

Michael Jay Lab

Jay’s research projects involve the development and commercialization of drug formulations and targeted delivery systems.

alexander_kabanov

Alexander Kabanov Lab

Alexander Kabanov is the director of the Center for Nanotechnology in Drug Delivery. The center’s research focuses on safely and efficiently translating new therapeutic and imaging agents from bench to bedside with the goal of improving human health.

sam_lai

Sam Lai – Lai Research Group

Research in the Lai Lab focuses broadly on infectious diseases at mucosal surfaces, targeted drug delivery and nanoparticle-immune interactions using a variety of tools from biophysics, molecular biology, immunology and engineering.

juliane_nguyen

Juliane Nguyen Lab

The Nguyen lab conducts research that focuses on the design and engineering of novel nano-scale carriers based on genetically encoded materials, lipids, and polymers for the treatment of ischemia.

The nine-story, 340,000-square-foot building features world-class imaging equipment, including a hybrid MRI/PET whole body scanner, a 7-Tesla MRI whole body scanner and a cyclotron. UNC and Massachusetts General Hospital, in affiliation with Harvard University, are currently the only two academic medical centers in the country that have these three imaging devices in one location. Together, each device optimizes the capabilities of the others, making these devices some of the most powerful diagnostic imaging tools in the world.

Microparticle resiquimod for the treatment of visceral leishmaniasis

1R21AI123692-01 NIH 4/16 – 3/18

Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection

1R01AI125147-01 NIH 4/16 – 4/21

Nanofiber matrices to improve neural stem cell-mediated cancer therapy

1R01NS097507-01 NIH 7/16 – 6/21

Use of Autologous Macrophages for Sustained Delivery of GDNF as Treatment of Parkinson’s Disease

UNC TEG15-4849 E. Batrakova (PI) 09/01/2015 – 06/30/2016

Polypeptide Modification for Enhanced Brain Delivery

2 R01 NS051334 NIH/NINDS, Kabanov (PI) Batrakova (Co-I) 01/01/2010 – 2015

Integrate Immune, Biomaterial & Stem Cell Platform for Neuroprotection in Battlefield Injuries

W81XWH11-1-0700 DoD, Kabanov (PI) Batrakova (Co-I) 08/29/2011 – 08/28/2014

Nanofiber matrices to improve neural stem cell-mediated cancer therapy

R01NS097507 NIH 06/01/2016-05/30/2021

Engineering stem cell therapies to understand and overcome glioblastoma adaption

R01NS099368 NIH 11/01/2017-10/31/2022

Personalized Neural Stem Cell Therapy for Cancer

R41TR001789 NIH 06/15/2017-06/14/2018

Program in PharmacoEngineering: Integrating Engineering with Pharmaceutical Sciences to Improve the Delivery of Therapeutic and Diagnostic Agents

North Carolina General Assembly 06/01/2015-
06/01/2018

Transdifferentiation: A novel approach to personalized cancer therapy

UNC Eshelman Institute for Innovation 11/01/2015-
06/01/2018

Systemic Stem Cell Therapy for Multi-organ Metastatic Breast Cancer

UNC Eshelman Institute for Innovation 06/01/2016-
05/31/2018

Game-changing Research Incentive Program: 3D Printing of Fibrous Tissue Engineered Medical Products

North Carolina State University 02/01/2017-
12/31/2020

Hepatic non-viral gene therapy

1 R01 DK100664 NIH 2013-2018

Nano Approaches to Modulate Host Cell Response for Cancer Therapy

1U54CA198999-01 NIH 2015-2020

Pharmacoengineering: Integrating Engineering with Pharmaceutical Sciences to Improve the Delivery of Therapeutic and Diagnostic Agents

UNC-GA M. Jay (Co-PI); Ligler (Co-PI) 02/15/2015-02/14/2018

This grant will fund two large projects related to immunoengineering and stem cell therapies for junior faculty, and will provide programmatic infrastructural support.

C2E2-An Orally Administered Radionuclide Decorporation Agent

1R44AI115751-01 N/L 07/01/2015-06/30/2017

This Direct-to-Phase II SBIR proposal is for IND-enabling work for a radionuclide decorporation drug.

Targeted Magneto-Mechanic Nanotherapeutics for Cancer

1R21CA220148 NIH NCI 08/01/17 – 07/31/20

Systemic Targeting of Mononuclear Phagocytes for Parkinson’s Disease Gene Therapy

Eshelman Institute for Innovation 06/01/17 – 5/31/19

Magneto-Mechanical Cancer Nanotherapeutics

Eshelman Institute for Innovation 06/01/16 – 5/31/18

Innovative Research in Cancer Nanotechnology (IRCN): Targeted Core Shell Nanogels for Triple Negative Breast Cancer

U01CA198910-01 NIH/NCI 8/14/15-7/31/2020

Carolina Cancer Nanotechnology Training Program (C-CNTP)

1T32CA196589-01 NIH/NCI 7/01/15 – 6/30/20

Carolina Center for Cancer Nanotechnology Excellence (C-CCNE): Nano Approaches to Modulate Host Cell Response for Cancer Therapy; Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer

NIH/NCI 09/15/15-07/31/20

Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy

R01CA184088 NIH/NCI 01/01/15 – 12/31/19

CAREER: Biophysical Investigations of Immune-Mediated Pathogen Trapping in Mucus

1151477 S. Lai (PI) 04/2012 – 03/2017

Harnessing Antibody-Mucin Interactions to Control Microbial Communities in the Gut

2013-39274 Packard Foundation, Lai (PI) 12/2013 – 11/2018

Research Program in Immunoengineering

NC General Assembly – Research Opportunities Initiative S. Lai (PI) 07/2015 – 06/2018

Development of novel sperm-binding antibodies

R56HD095629-01 Eunice Kennedy Shriver National Institute of Child Health and Human Development 8/2017 – 7/2018

Young Innovators Program: an immersive research experiential program at the UNC Eshelman School of Pharmacy

Burroughs Wellcome Foundation 6/2018 – 5/2021

 

Gene delivery to muscle and nerve for laminin-α2-deficient MD (MDC1A)

1R01NS079568 NIH/NINDS 04/01/13 – 03/31/18

Gene delivery for fukutin-related protein deficiencies

R01 NS082536 NIH/NINDS, Xiao 04/01/13 – 03/31/17

Assays for Duchenne Muscular Dystrophy gene therapy products

Bamboo Therapeutics Inc 5/2016-4/2018

Targetable and Regulatable Gene Delivery Platform Technology for Gene Therapy

Eshleman Institute for Innovation 5/2017-6/2019
  1. Chen N, Johnson M, Collier M, Bachelder E, Ainslie K. Tunable Degradation of Acetalated Dextran Microparticles Enables Controlled Vaccine Adjuvant and Antigen Delivery to Modulate Adaptive Immune Response. Journal of Controlled Release. 10 March 2018: 147-159
  2. Graham-Gurysh EG, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR, Hingtgen S, Ainslie KM. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Mol Pharm. 2018 Jan 17.
  3. Peine, KJ; Chen, N; Bachelder EM; Ainslie KM. Handbook of Research on Novel Approaches for Drug Delivery (Chapter: Drug Delivery Strategies for Tolerogenic Therapy for Autoimmune Diseases in an Antigen-Specific Manner) IgI Global, New York (2017).
  4. Collier MA, Peine KJ, Gautam S, Oghumu S, Varikuti S, Borteh H, Papenfuss TL, Sataoskar AR, Bachelder EM, Ainslie KM. “Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.” Int J Pharm. 2016 Jan 5;499(1-2):186-194.
  5. Gallovic MD, Montjoy DG, Collier MA, Do C, Wyslouzil BE, Bachelder EM, Ainslie KM. “Chemically modified inulin microparticles serving dual function as a protein antigen delivery vehicle and immunostimulatory adjuvant.” Biomater Sci. 2016 Jan 11.
  6. Duong AD, Collier MA, Bachelder EM, Wyslouzil BE, Ainslie KM. “One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading.” Mol Pharm. 2016 Jan 4;13(1):92-9.
  7. Bachelder EM, Pino EN, Ainslie KM. Acetalated Dextran: A Tunable and Acid-Labile Biopolymer with Facile Synthesis and a Range of Applications. Chem Rev. Online 2016 Dec 29.
  8. Duong AD, Collier MA, Bachelder EM, Wyslouzil BE, Ainslie KM “One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading. Mol Pharm. 2016 Jan 4;13(1):92-9.
  9. Gallovic MD, Montjoy DG, Collier MA, Do C, Wyslouzil BE, Bachelder EM, Ainslie KM. “Chemically modified inulin microparticles serving dual function as a protein antigen delivery vehicle and immunostimulatory adjuvant.” Biomater Sci. 2016 Jan 11.
  10. Collier MA, Peine KJ, Gautam S, Oghumu S, Varikuti S, Borteh H, Papenfuss TL, Sataoskar AR, Bachelder EM, Ainslie KM. “Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.” Int J Pharm. 2016 Jan 5;499(1-2):186-194.
  11. Hoang KV, Curry H, Collier MA, Borteh H, Bachelder EM, Schlesinger LS, Gunn JS, Ainslie KM. “Needle-free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge.” Antimicrob Agents Chemother. 2016 Jan 19.
  12. Collier MA, Gallovic MD, Bachelder EM, Sykes CD, Kashuba A, Ainslie KM. “Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable.” Pharm Res. 2016 Aug;33(8):1998-2009.
  13. Chen N, Collier MA, Gallovic MD, Collins GC, Sanchez CC, Fernandes EQ, Bachelder EM, Ainslie KM. “Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight.” Int J Pharm. 2016 Oct 15;512(1):147-57.
  14. Gallovic MD, Schully KL, Bell MG, Elberson MA, Palmer JR, Darko CA, Bachelder EM, Wyslouzil BE, Keane-Myers AM, Ainslie KM. Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure. Adv Healthc Mater. 2016 Oct;5(20):2617-2627.
  15. Collier MA, Bachelder EM, Ainslie KM. Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production. Pharm Res. 2016 Nov 28.
  1. Pan, D., Myerson, J., Brenner. J., Patel, P., Anselmo, A.C., Mitragotri, S., & Muzykantov, V. “Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells” Scientific Reports, 8, 1615, 2018.
  2. McHugh, K.J., Nguyen, T.D., Linehan, A.R., Yang, D., Behrens, A.M., Rose, S., Tochka Z.L., Tzeng, S.Y., Norman, J.J., Anselmo, A.C., Xu, X., Tomasic, S., Taylor, M.A., Lu, J., Guarecuco, R., Langer, R., & Jaklenec, A. “A new approach for creating fillable microparticles and other complex 3D microstructures” Science, 357, 1138-1142, 2017.
  3. Wibroe, P.P., Anselmo, A.C., Nilsson P.H., Gupta, V., Urbanics, R., Szebeni, J., Mitragotri, S., Mollnes, T.E., & Moghimi, S.M., “Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes” Nature Nanotechnology, 12, 589-594, 2017.
  4. Anselmo, A. C., Prabhakarpandian, B., Pant, K., & Mitragotri, S. “Clinical and Commercial Translation of Advanced Nanoparticle Systems: Challenges and Opportunities”, Translational Materials Research, 4(1), 2017.
  5. Anselmo, A. C. & Mitragotri, S. “Impact of Particle Elasticity on Particle-Based Drug Delivery Systems” Advanced Drug Delivery Reviews, 108, 51-67, 2017.
  6. Anselmo, A. C., McHugh, K.J., Webster, J., Langer, R., & Jaklenec, A. “Layer-by-Layer Encapsulation of Probiotics for Delivery to the MicrobiomeAdvanced Materials. 28(43), 9486-9490, 2016.
  1. Batrakova E.V. and Kim M.S. (2016) Development and Regulation of Exosome-based Therapy Products, WIREs Nanomedicine & Nanobiotechnology, under review.
  2. Haney M.H., Klyachko N.L., Zhao Y., Gupta R., He Z., Patel T., Piroyan A., Sokolsky M., Kabanov A.V., Batrakova E.V. (2015) Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy, J. Controlled Release, 2015 Mar 31; 207:18-30. doi: 10.1016/j.jconrel.2015.03.033. [Epub ahead of print] PMID: 25836593; The most downloaded article in JCR in last 90 days.
  3. Roy U., Hong Ding H., Kanthikeel S.P., Raymond A., Atluri V., Yndart A., Kaftanovskaya E.M., Batrakova E.V., Nair M. (2015) Preparation, Characterization and Efficacy of Anti-HIV Nanodrug Targeting to Microfold cell (M cell) of the Gut-associated lymphoid Tissue (GALT), Int J Nanomedicine. 18;10:5819-35. doi: 10.2147/IJN.S68348. PMID: 26425084.
  4. Kim M.S., Haney M.J., Zhao Y., Gupta R., Mahajan V., Inskoe E., Piroyan A., Sokolsky M., Okolie O., Hingtgen S.D., Kabanov A.V., and Batrakova E.V. (2015) Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells, Nanomedicine, Nov 13. pii: S1549-9634(15)00202-6. doi: 10.1016/j.nano.2015.10.012. PMID: 26586551.
  5. Batrakova E.V. and Kim M.S. (2015) Using naturally-equipped nanocarriers, exosomes, for drug delivery, J. Controlled Release, Aug 1. pii: S0168-3659(15)30042-0. doi: 10.1016/j.jconrel.2015.07.030. [Epub ahead of print] PMID: 26241750.
  6. Roy U., Barber P., Tse-Dinh Y.C., Batrakova E.V., Mondal D., and Nair M. (2015) Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections, Frontiers in Microbiology, Front Microbiol. 2015 Sep 17;6:948. doi: 10.3389/fmicb.2015.00948. eCollection 2015: PMID:26441882, [PubMed] PMCID: PMC4585023.
  7. Klyachko N.L., Haney M.H., Zhao Y., Polak R., Cohen R.E., Rubner M.F. and Batrakova E.V. (2015) Monocyte-mediated delivery of polymeric backpacks to inflamed brain tissues, J Control Release, in preparation.
  8. Zhao Y., Haney M.J., Gupta R., Bohnsack J.R., He Z., Kabanov A.V., Batrakova E.V. (2014) GDNF-transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson’s Disease Mouse Model, PLoS One. Sep 17;9(9):PMID: 25229627.
  1. Sheets, K., Bago., J.R., Paulk, I.L., Hingtgen, S.D., Image Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds. JoVE (In Press)
  2. Bago, J.R., Okolie, O., Dumitru, R., Ewend, M.G., Hingtgen, S.D. Tumor-homing Cytotoxic Induced Neural Stem Cells for Cancer Therapy. Sci Transl Med 2017 Feb 1;9(375). pii: eaah6510. doi: 10.1126/scitranslmed.aah6510. PMID: 28148846
  3. Okolie, O., Bago, J.R., Schmid, R.S., Irvin, D.M., Bash, R.E., Miller, C.R., Hingtgen, S.D. Reactive Astrocytes Potentiate Tumor Aggressiveness in a Murine Glioma Resection Recurrence Model. Neuro Oncol. June 13, 2016 PMID: 27298311
  4. Bago, J.R., Pegna, G.L., Okolie, O., Mohiti-Asli, M., Loboa, E.G., Hingtgen, S.D. (2016). Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy for surgically resected glioblastoma. Biomaterials, (2016) Jun;90:116-25. PMID: 2701662
  5. Bago, J.R., Alfonso-Pecchio, A., Okolie, O., Dumitru, R., Rinkenbaugh, A., Baldwin, A.S., Miller, C.R., Magness, S.T., Hingtgen, S.D. (2016). Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastoma. Nat. Commun., Feb 2;7:10593. PMID: 26830441
  6. Bago, J.R., Pegna, G.L., Okolie, O., Hingtgen, S.D. (2016). Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer. Biomaterials, (2016) Apr;84:42-53. PMID: 26803410
  1. Wang, Y., Zhang, L., Xu, Z., Miao, L. and Huang, L. mRNA Vaccine with Antigen-Specific Check Point Blockade Induces an Enhanced Immune Response Against Established Melanoma. Molecular Therapy, in press, 2017. DOI: 10.1016/j.ymthe.2017.11.009, Epub November 21 2017.
  2. Ye, Y., Wang, C., Zhang, X., Hu, Q., Zhang, Y., Liu, Q., Wen, D., Milligan, J., Bellotti, A., Huang, L., Gianpietro, D. and Gu, Z. A Melanin-mediated Cancer Immunotherapy Patch. Science Immunology, 10 Nov 2017: Vol. 2, Issue 17, eaan5692; DOI: 10.1126/sciimmunol.aan5692.
  3. Liu, L., Wang, Y., Miao, L., Liu, Q., Musetti, S., Li., J. and Huang, L. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Molecular Therapy, in press, 2017.
  4. Liu, Q., Zhu, H., Liu, Y., Musetti, S. and Huang, L. BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunology, Immunotherapy, in press, 2017. doi: 10.1007/s00262-017-2079-7; ePub November 1 2017.
  5. Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A.W.H., Wong, J., Lai, P.B.S., Goodwin, T., Liu, R., Huang, L., Chen, Z., Chow, K.-L., To, K.-F. and Cheng, A.S.L. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. GUT, in press, 2017. DOI: 10.1136/gutjnl-2017-314032; Epub September 22 2017.
  6. Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C., Goodwin, T., Dorosheva, O., Liu, R., Huang, L. Transient and Local Expression of Chemokine and Immune Checkpoint Traps to Treat Pancreatic Cancer. ACS Nano, 11: 8690–8706, 2017.
  7. Goodwin, T.J., Shen, L., Hu, M., Li, J., Feng, R., Dorosheva, O. Liu, R. and Huang, L. Liver Specific Gene Immunotherapies Resolve Immune Suppressive Ectopic Lymphoid Structures in Microniche of Liver Metastases, Prolonging Survival. Biomaterials, 141:260-271, 2017. Epub 2017 Jul 6. PMCID: PMC5557391
  8. Goodwin, T.J. and Huang, L. Investigation of Phosphorylated Adjuvants Co-encapsulated with a Model Cancer Peptide Antigen for the Treatment of Colorectal Cancer and Liver Metastasis. Vaccine, 35:2550-2557, 2017. DOI: 10.1016/j.vaccine.2017.03.067. Published online April 3, 2017. PMCID: PMC5448460.
  9. Hu, K., Miao, L., Goodwin, T.J, Li, J., Liu, Q. and Huang, L. Quercetin Remodels the Tumor Microenvironment to Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. ACS Nano, 11(5):4916-4925, 2017. DOI: 10.1021/acsnano.7b01522. Published online April 21, 2017.
  10. Satterlee, A.B., Attayek, P., Midkiff, B. and Huang, L. A Dosimetric Model for the Heterogeneous Delivery of Radioactive Nanoparticles In Vivo: A Feasibility Study. Radiation Oncology, 12:54, 2017. DOI 10.1186/s13014-017-0794-z. PMCID: PMC5356254.
  11. Shi, K., Zhao, Y., Miao, L., Satterlee, A.B., Haynes, M.T., Luo, C., Musetti, S. and Huang, L. Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition. Molecular Therapy, 25(7):1567-1579, 2017. doi: 10.1016/j.ymthe.2017.02.008. Published online March 5, 2017. PMCID: PMC5498803.
  12. Cheng, L. Wang, Y. and Huang, L. Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-Inflammatory Microenvironment in the Lymph Node. Molecular Therapy, 25(7):1665-1675, 2017. doi: 10.1016/j.ymthe.2017.02.007. Published online March 8, 2017. PMCID: PMC5498801.
  13. Satterlee, A.B., Rojas, J.D., Dayton, P.A. and Huang, L. Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy. Theranostics, 7:253-269, 2017. PMCID: PMC5197062.
  14. Huo, M., Zhao, Y., Satterlee, A.B., Wang, Y., Xu, Y. and Huang, L. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. Journal of Controlled Release, 245:81-94, 2017. Published online 15 November 2016. PMCID: PMC5222779.
  15. Miao, L., Liu, Q., Lin, C.M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W.Y. and Huang, L. Targeting Tumor-associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. Cancer Research, 77(3); 719–731, 2017. PMCID: PMC5290135.
  16. Goodwin, T.J. and Huang, L. On the article “Findings questioning the involvement of Sigma-1 receptor
  17. Xiong, Y., Zhao, Y., Miao, L., Lin, C.M. and Huang, L. Co-Delivery of Polymeric Metformin and Cisplatin by Self-Assembled Core-Membrane Nanoparticles to Treat Non-Small Cell Lung Cancer. Journal of Controlled Release, 244: 63–73, 2016. Published online 10 November 2016. PMCID: PMC5515375.
  18. Luo, C., Sun, J., Sun, B., Liu, D., Miao, L. Goodwin, T.J., Huang, L. and He, Z. Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine. Small, 12(46):6353-6362, 2016. Published online 30 September 2016. PMCID: PMC5206766.
  19. Qiu, N., Liu, X., Zhong, Y., Zhou, Z., Piao, Y., Miao, L., Zhang, Q., Tang, J., Huang, L. and Shen, Y. Esterase-Activated Charge-Reversal Polymer for Fibroblast-Exempt Cancer Gene Therapy. Advanced Materials, 28(48):10613-10622, 2016. DOI: 10.1002/adma.201603095, 2016.
  20. Miao, L., Newby, J., Lin, C., Zhang, L., Xu, F., Kim, W.Y., Forest, M.G., Lai, S.K., Milowsky, M.I., Wobker, S.E. and Huang, L. The Binding Site Barrier Elicited by Tumor Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. ACS Nano, 10:9243-9258, 2016. Published online 24 September 2016. PMCID: PMC5515694.
  21. Haynes, M. and Huang, L. Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. ACS Applied Materials & Interfaces, 8:24361-24367, 2016. PMCID: PMC5512567.
  22. Goodwin, T.J., Zhou, Y., Musetti, S.N., Liu, R. and Huang, L. Local and Transient Gene Expression Primes the Liver to Resist Cancer Metastasis. Science Translational Medicine, 8(364):364ra153, 2016. PMID: 27831902. PMCID: PMC5512420.
  23. Luo, C., Sun, J., Liu, D., Sun, B., Miao, L., Musetti, S., Li, J., Han, X., Du, Y., Li, L., Huang, L. and He, Z. Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy. Nano Letters, 16:5401-5408, 2016. Epub 2016 Aug 8.
  24. Luo, C. Miao, L., Zhao, Y., Musetti, S., Wang, Y. Shi, K. and Huang, L. A Novel Cationic Lipid with Intrinsic Antitumor Activity to Facilitate Gene Therapy of TRAIL DNA. Biomaterials, 102:239-248, 2016. Epub 2016 Jun 16. PMCID: PMC5512171.
  25. Lu, Y., Wang, Y., Miao, L., Haynes, M., Xiang, G. and Huang, L. Exploiting In Situ Antigen Generation and Immune Modulation to Enhance Chemotherapy Response in Advanced Melanoma: A Combination Nanomedicine Approach. Cancer Lett., 379(1):32-38, 2016. Epub 2016 May 25. PMID: 27235608.
  26. Li, Y., Wu, Y., Huang, L., Miao, L. Zhou, J. Satterlee, A.B. and Yao, J. Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. Journal of Controlled Release, 228:107-119, 2016. Epub 2016 Mar 3. PMID: 26941036.
  1. J Fu, E Pacyniak, MGD Leed, MP Sadgrove, L Marson and M Jay. Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases. J Pharm Sci,, in press.
  2. JE Huckle, E Altun, M Jay and RC Semelka. Gadolinium Deposition In Humans: When Did We Learn That Gadolinium Was Deposited In Vivo? Investigative Radiology, Epub ahead of print.
  3. LMB Burke, M Ramalho, M Al Obaidy, E Chang, MD, E Wu, M Jay and RC Semelka. Self-Reported Gadolinium Toxicity: A Survey of Patients with Chronic Symptoms They Ascribe to Gadolinium Exposure. Submitted to American Journal of Roentgenology.
  4. JE Huckle, MP Sadgrove, Marina GD Leed, YT Yang, RJ Mumper and M Jay. C2E2: A di-ethyl ester prodrug of DTPA as an orally bioavailable radionuclide decorporation agent, Submitted to AAPS Journal.
  5. J Fu, M Sadgrove, L Marson and M Jay. Biotransformation capacity of carboxylesterase in skin and keratinocytes for pentaethyl ester prodrug of DTPA. Submitted to Drug Met Disposition.
  6. JE Huckle, MP Sadgrove, RJ Mumper and M Jay. Species-Dependent Chelation of 241Am by DTPA Di-ethyl Ester. Health Physics. 108:443-450 (2015).
  7. J Fitzsimmons and M Jay. Preparative scale separation of ethyl esters of diethylenetriaminepentaacetic acid by flash chromatography. J Radioanalytical Nucl Chem. 305:329–336 (2015).
  8. JE Huckle, MP Sadgrove, E Pacyniak, MGD Leed, WM Weber, M Doyle-Eisele, RA Guilmette, BJ Agha, RL Susick, RJ Mumper and M Jay. Orally Administered DTPA Di-ethyl Ester for Decorporation of 241Am: Efficacy in a Dog Inhalation-Contamination Model and Safety Assessment in Dogs. Int J Rad Biol., 91(7):568-75 (2015).
  9. P Phetpornpaisan, P Tippayawat, M Jay and K Sutthanut. A Local Thai Cultivar Glutinous Black Rice Bran: A Source of Functional Compounds in Immunomodulation, Cell Viability and Collagen Synthesis, and Matrix Metalloproteinase-2 and -9 Inhibition. J Functional Foods. 7:650-661 (2014).
  10. YT Yang, AJ Di Pasqua, Y Zhang, K Sueda and M Jay. Solid dispersions of the penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA): formulation design and optimization studies. Pharm Dev Tech. 19:806-812 (2014).
  11. YT Yang, Y Shi, M Jay and AJ Di Pasqua. Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward non-small cell lung cancer cells when delivered in liposomal nanoparticles. Chem Res Toxicol. 27:946-948 (2014).
  12. K Sueda, MP Sadgrove, JE.Huckle, MGD Leed, WM Weber, M Doyle-Eisele, RA Guilmette and M Jay. Orally Administered DTPA Penta-Ethyl Ester for the Decorporation of Inhaled 241Am. J Pharm Sci. 103:1563–1571 (2014).
  1. Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL, Kabanov AV, Batrakova EV. (2018) Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 14(1):195-204. doi: 10.1016/j.nano.2017.09.011. Epub 2017 Oct 2. PMID: 28982587
  2. Jiang Y., Fay J.M., Poon C‐, Vinod N., Zhao Y., Bullock K., Qin S., Manickam D.S., Yi X., Banks W.A., Kabanov A.V. (2018) Nanoformulation of brain-derived neurotrophic factor with target receptor-triggered-release in the central nervous system, Adv. Funct. Mat DOI: 10.1002/adfm.201703982
  3. Yuan D, Zhao Y, Banks WA, Bullock KM, Haney M, Batrakova E, Kabanov AV (2017) Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials. 142:1-12. doi: 10.1016/j.biomaterials.2017.07.011. PMCID: PMC5603188
  4. Yuan D, Yi X, Zhao Y, Poon CD, Bullock KM, Hansen KM, Salameh TS, Farr SA, Banks WA, Kabanov AV (2017) Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity. J. Control. Release. 2017 Oct 10;263:172-184. doi: 10.1016/j.jconrel.2017.03.029. Epub 2017 Mar 24. PMCID: PMC5603367
  5. Nukolova NV, Aleksashkin AD, Abakumova TO, Morozova AY, Gubskiy IL, Kirzhanova ЕА, Abakumov MA, Chekhonin VP, Klyachko NL, Kabanov AV (2017) Multilayer polyion complex nanoformulations of superoxide dismutase 1 for acute spinal cord injury. J Control Release. 2017 Dec 2; 270:226-236. doi: 10.1016/j.jconrel.2017.11.044. PMID: 29196042
  6. Natarajan G, Perriotte-Olson C, Bhinderwala F, Powers R, Desouza CV, Talmon GA, Yuhang J, Zimmerman MC, Kabanov AV, Saraswathi V (2017) Nanoformulated copper/zinc superoxide dismutase exerts differential effects on glucose vs lipid homeostasis depending on the diet composition possibly via altered AMPK signaling. Transl Res. pii: S1931-5244(16)30488-1. doi: 10.1016/j.trsl.2017.08.002. PMID: 28867395
  7. Lucas AT, Herity LB, Kornblum ZA, Madden AJ, Gabizon A, Kabanov AV, Ajamie RT, Bender DM, Kulanthaivel P, Sanchez-Felix MV, Havel HA, Zamboni WC (2017) Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs. Int J Pharm. 526(1-2):443-454. doi: 10.1016/j.ijpharm.2017.04.079.
  8. Klyachko NL, Polak R, Haney MJ, Zhao Y, Gomes Neto RJ, Hill MC, Kabanov AV, Cohen RE, Rubner MF, Batrakova EV (2017) Macrophages with cellular backpacks for targeted drug delivery to the brain. Biomaterials. 140:79-87. doi: 10.1016/j.biomaterials.2017.06.017.
  9. Efremenko EN, Lyagin IV, Klyachko NL, Bronich T, Zavyalova NV, Jiang Y, Kabanov AV (2017) A simple and highly effective catalytic nanozyme scavenger for organophosphorus neurotoxins. J. Control. Release, 247(10), 175–81
  10. Golovin YI, Golovin DY, Klyachko NL, Majouga AG, Kabanov AV (2017) Modeling drug release from functionalized magnetic nanoparticles actuated by non-heating low frequency magnetic field. J. Nanoparticle Research, 19: 64. https://doi.org/10.1007/s11051-017-3754-5
  11. Golovin YI, Klyachko NL, Majouga AG, Sokolsky M, Kabanov AV (2017) Theranostic multimodal potential of magnetic nanoparticles actuated by non-heating low frequency magnetic field in the new-generation nanomedicine. J. Nanoparticle Research, 19(2): 63. https://doi.org/10.1007/s11051-017-3746-5
  12. Golovin YI, Gribanovsky SL, Golovin DY, Zhigachev AO, Klyachko NL, Majouga AG, Sokolsky M, Kabanov AV (2017) The dynamics of magnetic nanoparticles exposed to non-heating alternating magnetic field in biochemical applications: theoretical study. J. Nanoparticle Research, 19 (2): 59. https://doi.org/10.1007/s11051-017-3753-6
  13. Gaymalov Z, Kabanov A (2017) RECOPE: How to succeed in bringing ideas from academia to market without compromising ingenuity. Nanomedicine: Nanotechnology, Biology and Medicine 13(3):795-800. doi: 10.1016/j.nano.2016.10.007. Epub 2016 Oct 29
  1. Fix SM, Nyankima AG, McSweeney MD, Tsuruta JK, Lai SK, Dayton PA. (2017) Accelerated clearance of ultrasound contrast agents containing polyethylene glycol (PEG) is associated with the generation of anti-PEG antibodies.  Ultrasound in Medicine and Biology.
  2. McSweeney MD, Versfeld ZC, Carpenter DM, Lai SK§.  (2017) Physician awareness of immune responses to polyethylene glycol-drug conjugates. Clinical and Translational Science. Accepted.
  3. Newby J, Seim I, Lysy M, Ling Y, Huckaby J, Lai SK, Forest G. (2017) Technological strategies to estimate and control diffusive passage times through the airway mucus barrier in mucosal drug delivery.  Adv Drug Deliv Rev. DOI: 10.1016/j.addr.2017.12.002    [Impact 15.6]
  4. Huckaby J, Lai SK§ (2017) PEGylation for enhancing nanoparticle diffusion in mucus. Adv Drug Deliv Rev. DOI: 10.1016/j.addr.2017.08.010   [Impact 15.6]
  5. Parker CL, Yang Q, Yang B, McCallen JD, Park SI, Lai SK (2017)  Multivalent interactions between streptavidin-based pretargeting fusion proteins and cell receptors impede efficient internalization of biotinylated nanoparticles. Acta Biomaterialia. 63:181-189  [Impact 6.0]
  6. McCallen J*, Prybylski J*, Yang Q, Lai SK§. (2017) Cross-reactivity of anti-PEG antibodies to other polymers containing C-C-O backbone. ACS Biomaterials Science & Engineering. 3(8):1605–1615.
  7. Newby J*, Schiller J*, Wessler T, Edelstein J, Forest MG, Lai SK.  (2017) A blueprint for robust crosslinking of mobile species in biogels using third-party molecular anchors with short-lived anchor-matrix bonds. Nature Communications. 8(1):833  [Impact 12.1]
  8. Yang Q, Parker CL, Lin Y, Press OW, Park SI, Lai SK. (2017) Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens.  J Controlled Release 255:73-80.  PMID: 28363519  [Impact 7.7]
  1. P Shi, M Liao, BC Chuang, R Griffin, J Shi, M Hyer, JK Fallon, PC Smith, C Li, CQ Xia. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.  2017, 16:1-11.  PMID: 29098941.
  2. B Achour, A Dantonio, M Niosi, JJ Novak, JK Fallon, J Barber, PC Smith, A Rostami-Hodjegan, TC Goosen. Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity.  Drug Metab Dispos. 2017, 4: 1102-1112.  PMID: 28768682
  3. CG Thompson, JK Fallon, M Mathews, P Charlins, L Mulder, M Kovarova, L Adamson, N Srinivas, A Schauer, C Sykes, P Luciw, JV Garcia, R Akkina, PC Smith, ADM Kashuba. Multimodal analysis of drug transporter expression in gastrointestinal tissue.AIDS. 2017 Jun 5. PMID: 28590331.
  4. JK Fallon, PC Smith, CQ Xia, MS Kim. Quantification of four efflux drug transporters in liver and kidney across species using targeted quantitative proteomics by isotope dilution nanoLC-MS/MS.   Pharmaceut Res 33: 2280-2288 (2016).  PMID: 27356525
  5. GN Asher, JK Fallon, PC Smith. UGT concentrations in human rectal tissue after multidose, oral curcumin.   Pharmacol Res Perspect. 2016 Feb 23;4(2). PMID: 27069633
  1. Bulaklak K, Xiao X. (2017) Therapeutic advances in musculoskeletal AAV targeting approaches. Curr Opin Pharmacol. 34:56-63.
  2. Hui Zheng1,2#, Chunping Qiao1#, Ruhang Tang1,  Jianbin Li1, Karen Bulaklak1, Zhenhua, Huang1, Chunxia Zhao1,  Yi Dai1 , Juan Li1 & Xiao Xiao (2017) Follistatin N-terminus differentially regulates muscle size and fat in vivo. Experimental and Molecular Medicine. Exp Sep 15;49(9).
  3. Charles H. Vannoy, Will Xiao, Peijuan Lu, Xiao Xiao, Qi L. Lu (2017) Efficacy of Gene Therapy is Dependent on Disease Progression in Dystrophic Mice with Mutations in the FKRP Gene. Molecular Therapy – Methods & Clinical Development. 8;5:31-42.
  4. Vannoy CH, Zhou H, Qiao C, Xiao X, Bang AG, Lu QL (2017) Adeno-Associated Virus-Mediated Mini-Agrin Delivery Is Unable to Rescue Disease Phenotype in a Mouse Model of Limb Girdle Muscular Dystrophy Type 2I. Am J Pathol. 2017 Feb;187(2):431-440.
  5. Jiang J, Shen G, Li J, Qiao C, Xiao B, Yan H, Wang DW, Xiao X. (2017) Adeno-associated virus-mediated expression of myostatin propeptide improves the growth of skeletal muscle and attenuates hyperglycemia in db/db mice. Gene Ther. 24(3):167-175

Research Centers

The Center for Nanotechnology in Drug Delivery, part of a campus-wide nanomedicine initiative at UNC, brings together scientists to create nano-scale pharmaceutical innovations for therapeutic and diagnostic purposes. The Center’s research focuses on safely and efficiently translating new therapeutic and imaging agents from bench to bedside with the goal of improving human health. CNDD serves to unify existing diverse technical and scientific expertise in biomedical and material science research at UNC through its world-class interdisciplinary drug delivery and nanomedicine program.The primary goal of the CNDD is to provide a foundation for synergistic research that translates into clinical benefits for diseases that currently have limited treatment options while simultaneously developing a critical and “visionary” area of science in which the state of North Carolina is a world leader.


Research Cores

Nanomedicines Characterization Core Facility

The NCore accelerates the translation of new molecular-entity discoveries into human clinical trials through comprehensive characterization of novel nanomedicines and nanomaterials. Its services are organized into three independent blocks: physicochemical assays, comprehensive physicochemical characterization studies, and bioassays characterization package services.

NMR Facility

The NMR Facility in the School of Pharmacy serves the needs of research groups from across the campus of the University of North Carolina. The facility houses a Varian Gemini 300 and an Inova 500.


Collaboration and Partnership

We are partnering across the campus, state, nation and around the world to advance research and advance knowledge and treatment for patients to discover solutions for the world’s most challenging health issues.

UNC Health Sciences Campus

The School is part of the University of North Carolina at Chapel Hill, a major research university with a large teaching hospital and schools of medicine, public health, nursing, and dentistry.

  • Ranked 5th nationally for federal research among all universities
  • $1.1 billion in sponsored research from all sources annually
  • Eleventh largest research university in research volume and annual expenditures

 

Eshelman Institute for Innovation_logo

Eshelman Institute for Innovation

The Eshelman Institute for Innovation was established in 2014 with a $100 million commitment from Dr. Fred Eshelman.  The Institute encourages collaborations between universities, research institutions, foundations and industry that accelerate groundbreaking science from the bench to the patient by funding and translating ‘top tier’ scientific solutions to the market with speed.  Learn more here.

Learn More


rtp_logo

Research Triangle Park

UNC anchors one corner of North Carolina’s famed Research Triangle Park, which hosts an abundance of pharmaceutical, biotech, and health-care companies. This environment offers many opportunities for collaboration in research, education, and patient care with partners in academia, industry, and health care.


Pinnacle-Hill-Logo

Pinnacle Hill

The University of North Carolina at Chapel Hill and Deerfield Management have entered into a partnership to create Pinnacle Hill, a company seeking to discover new medicines to address the significant unmet medical needs of our times. Deerfield will invest up to $65 million of targeted funding through Pinnacle Hill, as well as providing significant drug development expertise to advance promising therapeutic research at UNC-Chapel Hill.  Learn more here.

Learn More


 

PharmAlliance_logo

PharmAlliance

PharmAlliance is a unique international partnership between three global leaders in pharmacy education, the University of North Carolina at Chapel Hill, Monash University, and University College   London. PharmAlliance partners work collaboratively to inspire and train tomorrow’s professional leaders and practitioners to transform education delivery and address major research challenges in pharmacy and the pharmaceutical sciences.

Learn More


SGC+logo

Structural Genomics Consortium

The SGC (Structural Genomics Consortium) is a not-for-profit, public-private partnership that performs basic science of relevance to drug discovery. Research is conducted at several sites around the world to produce reagents, proteins, antibodies, assays, and data that support exploration of the human genome. All material and intellectual output of the SGC is placed in the public domain for use without restriction. The first SGC laboratory to operate in the USA is located in the UNC Eshelman School of Pharmacy. Learn more here.

Learn More